VacciTalks: Vaccine Development from Bench to Patient: Myths and Reality 

Welcome to VacciTalks by Alira Health – exclusive educational appointments with the leading vaccine experts

Published on:
January 21, 2022

Is vaccine recommendation after registration really needed? Is regulatory approval the same as a recommendation? Can a research laboratory bring its own vaccine to a market?

On the 24th of February for the first VacciTalk episode “Vaccine Development from Bench to Patient: Myths and Reality ” we sat down with Prof. Dr. Joe Schmitt, vaccine expert with 40 years of experience, and discovered answers to these and many other questions and debunked some of the most common myths related to vaccine development in a live discussion.

Watch the replay of VacciTalk “Vaccine Development from Bench to Patient: Myths and Reality ” and learn about:
  • The common misconceptions related to the vaccine development
  • Challenges these misconceptions can cause
  • Ways to overcome them
Joe Schmitt

Joe is board certified in paediatrics, infectious diseases, microbiology, and epidemiology and held a chair as professor of vaccine development at the Gutenberg University, Mainz, Germany.

Joe’s clinical studies were cornerstones for global licenses of acellular pertussis and respective combination vaccines.  Joe was a member (1995-2007) and chair of the German vaccination advisory board (STIKO) for 3 consecutive terms (1997-2007) and advisor to the Paul Ehrlich Institute (PEI) and different WHO committees, including SAGE and the GACVS-groups. He was the Global Head, Medical Affairs with Novartis Vaccines during the time of the influenza pandemic (about 2010) and he joined Pfizer in 2011 and was Vice President for Medical-, Developmental-, Scientific- and Clinical-Affairs (MDSCA) and Global Lead Viral Vaccines until May 2021.  

Currently, Joe is Editor-in-Chief with Global Health Press (GHP) in Singapore and he is also Strategic and Scientific Advisor with “Vaccelerate” at the Cologne University, Germany. 

Our hosts 

Bernd Schollmeier, Vice President, Global Market Access Vaccines 
Bernd Schollmeier

A vaccine expert with more than 30 years of experience, Bernd has been responsible for a range of global pricing and market access initiatives for vaccines in the international pharmaceutical companies — from delivering a range of solutions across development and strategic market access considerations for trial design to value demonstration in P&R negotiations as well as commercialization strategies.  

Kenny Carberry, Associate Director, Clinical Development 
Kenny Carberry

Kenny’s background covers a wide array of indications across pharma, medical devices, and digital health. He has multiple years of experience in clinical trial operations and management and offers a unique perspective on the clinical development lifecycle from generating a comprehensive strategy through executing a successful trial. 

About VacciTalks

VacciTalks is a series of unique appointments with the Key Opinion Leaders of the vaccine world. During each of the episodes, our hosts Bernd Schollmeier and Kenny Carberry will sit down with their guests and talk about the topics that disrupt the vaccine world right now – from development challenges to COVID-19 impact, new technologies, and much more.  

Follow us on LinkedIn and never miss the next VacciTalk!  

Related news

Blog April 17, 2023
Reimbursement of Rare Disease Drugs in Italy: Challenges and Hopes for the Future
When it comes to rare diseases, Italy has done a good job in bringing EMA-approved drugs, including orphan drugs, to the Italian market. But  multiple challenges exist, many of which(...)
Italy Market Access Pharma Rare Disease Real-World Evidence (RWE)
Blog April 17, 2023
Pharmaceutical Market Access in the UK: A Changing Landscape
Start reading this interview with Rachel Fyson to gain insight into the changing landscape of market access in the United Kingdom.
Market Access Pharma UK
Blog April 14, 2023
Lifecycle Optimization: The Path to Commercial Success
Pharmaceutical and biotech companies constantly focus on product innovation. But how can you also increase your effectiveness in order to be as commercially competitive and efficient as possible?
Market Access MedTech Pharma
News April 5, 2023
Alira Health Joins EMIG to Advance Market Access in the UK
We are pleased to announce that Alira Health has joined the Ethical Medicines Industry Group (EMIG), a multi-stakeholder network and trade association that represents the interests(...)
Market Access Patient Centricity UK
Blog March 20, 2023
The State of Market Access in Italy 2023
To learn about the state of market access in Italy today, we spoke with Giovanni Firenze, Director of Market Access Italy for Alira Health, who attended the recent 2023 Conferenza Nazionale(...)
Drug Development Italy Market Access Pharma
Events March 6, 2023
World EPA Congress 2023
We are pleased to share that we will be participating in World EPA Congress 2023 as speakers and sponsors. World Evidence, Pricing and Access Congress is Europe’s largest congress(...)
Biotech Market Access Pharma Real-World Evidence (RWE)
Blog March 6, 2023
Market Access in Catalonia: 2022 Trends and What’s Next
Alira Health contributed to the recently published 2022 BioRegion Report, the most extensive analysis of the assets, achievements, and trends in the life sciences and healthcare sector(...)
Biotech Market Access MedTech Spain
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.